US2023159507A1PendingUtilityA1

Modulators of hemoglobin

Assignee: GLOBAL BLOOD THERAPEUTICS INCPriority: Nov 19, 2018Filed: Nov 21, 2022Published: May 25, 2023

Est. expiryNov 19, 2038(~12.3 yrs left)· nominal 20-yr term from priority

Inventors:Zhe Li

C07D 265/30A61K 31/541C07D 401/06A61K 31/4545C07D 211/22A61P 7/06C07D 413/06C07D 403/06C07D 279/12A61K 31/5377C07D 401/14C07D 207/08C07D 417/06C07D 401/10C07D 487/04

PatentIndex Score

Cited by

References

Claims

Abstract

The present disclosure relates generally to compounds and pharmaceutical compositions suitable as modulators of hemoglobin, and methods for their use in treating disorders mediated by hemoglobin.

Claims

exact text as granted — not AI-modified

1 .- 20 . (canceled) 
     
     
         21 . A method for increasing oxygen affinity of hemoglobin S in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of formula: 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof. 
     
     
         22 . The method of  claim 21 , comprising administering to the subject a therapeutically effective amount of a compound of formula: 
       
         
           
           
               
               
           
         
       
     
     
         23 . A method for treating a disorder mediated by hemoglobin in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of formula: 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof. 
     
     
         24 . The method of  claim 23 , comprising administering to the subject a therapeutically effective amount of a compound of formula: 
       
         
           
           
               
               
           
         
       
     
     
         25 . The method of  claim 23 , wherein the hemoglobin is sickle hemoglobin. 
     
     
         26 . A method for treating sickle cell disease in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of formula: 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof. 
     
     
         27 . The method of  claim 26 , comprising administering to the subject a therapeutically effective amount of a compound of formula:

Join the waitlist — get patent alerts

Track US2023159507A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.